

Vitamin D Status in Egyptian Patients with Cancer: A Possible Risk Factor

Thesis

Submitted for Partial Fulfillment of Master
Degree in Clinical and Chemical Pathology

By

Mahmoud Amin Youssef

MB BCh Ain-Shams University

Supervised By

Prof./ Aisha Yassin Abdel Ghaffar

*Professor of Clinical and Chemical Pathology
Faculty of Medicine - Ain Shams University*

Prof./ Nahla Mohamed Zakaria Yousef

*Professor of Clinical and Chemical Pathology
Faculty of Medicine - Ain Shams University*

Dr./ Rania Hamdy El-kabarity

*Assistant Professor of Clinical and Chemical Pathology
Faculty of Medicine - Ain Shams University*

Faculty of Medicine - Ain Shams University

2014

Acknowledgments

First thanks to **ALLAH** to whom I relate any success in achieving any work in my life.

I wish to express my deepest thanks, gratitude and appreciation to **Prof./ Aisha Yassin Abdel Ghaffar**, Professor of Clinical and Chemical Pathology for her meticulous supervision, kind guidance, valuable instructions and generous help. I was truly honored to work under her supervision.

I am deeply thankful to **Prof./ Nahla Mohamed Zakaria Yousef**, Professor of Clinical and Chemical Pathology for her help, support, active participation and guidance throughout this work.

I am deeply grateful for **Dr./ Rania Hamdy El-kabarity**, Assistant Professor of Clinical and Chemical Pathology, for her valuable help and guidance.

I would like to express my hearty thanks to all my family for their support till this work was completed.

Mahmoud Amin

List of Contents

Title	Page No.
List of Tables.....	i
List of Figures	iii
List of Abbreviations.....	iv
Introduction.....	1
Aim of the Work.....	4
Review of Literature	
▪ Vitamin D.....	5
▪ Vitamin D and Breast, Colon and Prostate Cancer	38
▪ Vitamin D and Cancer	55
Subjects and Methods	75
Results	82
Discussion	97
Summary.....	108
Conclusions.....	111
Recommendations	112
References	113
Arabic Sumamry	

List of Tables

Table No.	Title	Page No.
Table (1):	Action of Vitamin D in the immune system	37
Table (2):	Diagnostic work-up for early breast cancer.....	43
Table (3):	Comparison between controls and all patients regarding age.	82
Table (4):	Descriptive statistics of the various studied parameters among our cases & controls.....	83
Table (5):	Comparison between vitamin D level in the control group and other patients groups.....	84
Table (6):	Comparison between controls and all patients regarding frequency of vitamin D adequacy	85
Table (7):	Comparison between breast cancer group and prostate cancer group regarding different parameters studied.	87
Table (8):	Comparison between cancer colon group and prostate cancer group regarding different parameters studied.	88
Table (9):	Comparison between breast cancer group and colon cancer group regarding different parameters studied.....	89
Table (10):	Comparison between patients with metastasis and patients free of metastasis within all cases.....	90

List of Tables (Cont...)

Table No.	Title	Page No.
Table (11):	Comparison between patients with metastasis and patients free of metastasis within breast cancer, colon cancer and prostate cancer groups regarding vitamin D level.	91
Table (12):	Comparison between patients with adequate sun exposure and patients with inadequate sun exposure within all patients regarding vitamin D level.....	92
Table (13):	Comparison between patients with adequate sun exposure and patients with inadequate sun exposure within breast cancer and colon cancer groups regarding vitamin D level.....	94
Table (14):	Correlation study between vitamin D level and different parameters studied in controls, prostate, breast, colon cancer groups.....	95

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	Metabolism of vitamin D	7
Fig. (2):	Functional domains in human VDR along with the corresponding DNA (gene), protein and lipophilic ligand partners	16
Fig. (3):	Binding of VDR to its response element.	17
Fig. (4):	Comparison of vitamin D response elements (VDREs) from several vitamin D-responsive genes and other hormone receptor response elements	19
Fig. (5):	Putative molecular communications between vitamin D receptor (VDR) and the transcriptional complex.....	20
Fig. (6):	Effects of 1,25 Vitamin D on monocytes and dendritic cells	30
Fig. (7):	Mechanisms for innate and adaptive immune responses to vitamin D	32
Fig. (8):	Effects of 1.25 vitamin D on T cells	34
Fig. (9):	Actions of vitamin D on cells of immune system.....	36
Fig. (10):	Dysjunction–initiation–natural selection–overgrowth–metastasis–involution–transition.....	61
Fig. (11):	A working model for the cross-talk between cells in the epithelial, stromal and adipose compartments of the breast.....	65
Fig. (12):	Medium vitamin D level among all studied groups.....	84
Fig. (13):	Diagram illustrating the frequency of vitamin D adequacy among all studied groups.....	86
Fig. (14):	Diagram illustrating the difference between patients with adequate sun exposure and patients with inadequate sun exposure regarding vitamin D level.....	93
Fig. (15):	Correlation study between vitamin D and CA 15.3 among patients with Breast Cancer.....	96

List of Abbreviations

Abb.	Full term
25(OH)2D	25-hydroxy vitamin D
C/EBP β	Ccaat-enhancer-binding protein β
CDK	Cyclin dependent kinases (CDK)
CEA.....	Carcinoembryonic antigen (CEA)
DC	Dendritic cells
DINOMIT	Dysjunction–Initiation–Natural selection– Overgrowth–Metastasis–Involution–Transition
DNA	Deoxyribonucleic acid (DNA)
DRE	Digital rectal examination (DRE)
EGFR.....	Epidermal growth factor receptors
ER	Endoplasmic reticulum
FAP	Familial adenomatous polyposis (FAP)
FAP	Familial adenomatous polyposis (FAP)
FASL.....	Fas ligand.
FOBT	Faecal occult blood test (FOBT)
FXR.....	Farnesoid X receptor
HNPCC.....	Hereditary nonpolyposis colon cancer (HNPCC)
HNPCC.....	Hereditary non-polyposis colorectal cancer (HNPCC)
HUVEC.....	human umbilical vein endothelial cells
IL.....	Interleukin.
INF- γ	Gama interferon.
LCA.....	Lithocholic acid
MAPK	Mitogen-activated protein kinase
MARRS	Membrane associated, rapid response, steroid-binding
MBC.....	Metastatic breast cancer (MBC)
MHC	Major histocompatibility complex.
mOC.....	Mouse osteocalcin
MRI.....	Magnetic resonance imaging (MRI)
NK.....	Natural killer
NOD.....	Non-obese diabetic

List of Abbreviations (Cont...)

Abb.	Full term
PDDR.....	Pseudovitamin D-deficient rickets
PKC.....	Protein kinase C
PLA2	Phospholipase A2
PLC	Phospholipase C
PPV	Positive predictive value (PPV)
PSA	Prostate-specific antigen (PSA)
PTH.....	Parathyroid hormone
PXR.....	Pregnane X receptor
PXR.....	Retinoid X receptor
rOC	Rat osteocalcin
SCC	squamous cell carcinoma (SCC)
SPF	Sun protection factor
TDEC	tumor-derived endothelial cells (TDEC)
Th.....	T helper
TNF.....	Tumor necrosis factor.
UV-B	Ultra violet
VDBP	Vitamin D binding protein (VDBP)
VDR	Vitamin D receptor
VDR	Vitamin D receptor (VDR)
VDR	Vitamin D receptor.
VDREs	Vitamin D responsive elements
VSMCs.....	Vascular smooth muscle cells (VSMCs)

INTRODUCTION

Vitamin D is a fat-soluble vitamin that regulates calcium and bone homeostasis and also has diverse biological effects relevant to carcinogenesis. Modest amounts of vitamin D come from supplements and dietary sources such as fortified dairy products and cereals and fatty fish. However, the majority of vitamin D, up to 90%, is produced naturally in the body when UVB light hits a precursor molecule in the skin (*Raman et al., 2011*).

In the cancer research field, vitamin D has emerged as the most prolific topic in the last decade with work connecting it with risk reduction in various epithelial cancers. Aside from calcium homeostasis, vitamin D exerts a wide range of immunogenic and antiproliferative activities in the body. Of particular interest to the oncologists is the reduced incidence of breast, colon, and prostate cancers with higher sun exposure, higher intake, or higher serum levels of vitamin D. Vitamin D exerts its antiproliferative effect by binding to vitamin D receptor (VDR) found in various tissues and cells of the body. Several human genes contain vitamin D response elements (specific DNA sequences) that encode for proteins important in regulation of cell proliferation, differentiation, apoptosis, and angiogenesis. When serum vitamin D levels are suboptimal these activities are impaired, and as a result enhanced cellular

growth, neoangiogenesis, and cancer development take place (*Grant, 2002*).

Vitamin D from both diet and sun exposure is metabolized in the liver to 25-hydroxy vitamin D (25(OH)2D) and then further hydroxylated by 1 alpha hydroxylase enzyme in kidneys and other tissues like breast cells to 1,25- dihydroxy vitamin D (1,25 (OH)2D), the most biologically active form and the natural ligand for VDR. Serum concentration of 25(OH)2D is more sensitive to exogenous sources (dietary and supplemental intake) and endogenous production (through synthesis in the skin) of vitamin D. It also has a long half-life of 3 weeks, is the predominant form of vitamin D in plasma and the major storage form; hence the circulating 25(OH)2D is the best indicator of vitamin D status of the body (*Imtiaz et al., 2012*).

Numerous preclinical studies have shown that 1,25-(OH)2D inhibits cell proliferation, induces differentiation and apoptosis. However, several epidemiologic studies evaluating the association between vitamin D and colon or breast cancer risk have yielded inconsistent results. Some of these studies assessed the effects of dietary and supplemental intake of parenteral vitamin D, inspite of the fact that vitamin D endogenous production through sunlight exposure is the major source of vitamin D in the body (*Peters et al., 2012*). Vitamin D deficiency is also associated with secondary hyperparathyroidism which results in increased bone

resorption, release of calcium from bones, and may precipitate or exacerbate osteoporosis. Thus, these cancer patients must undergo a baseline metabolic bone evaluation with serum vitamin D levels, serum calcium levels and parathyroid hormone (PTH) status (*Imtiaz et al., 2012*).

AIM OF THE WORK

The aim of this work is to assess the frequency of vitamin D deficiency in Egyptian patients with colon, breast and prostate cancers, so as to determine whether these cancers are associated with vitamin D deficiency as a possible risk factor.

Chapter One

VITAMIN D

Introduction:

Vitamin D is a lipid-soluble vitamin which consists of steroid molecule structure. Vitamin D is not a pure vitamin because its requirements are not only fulfilled through consumption of food containing vitamin D but could also be synthesized by the body with the help of sun ray exposure (*Dusso et al., 2005*).

Structure and Synthesis:

The term vitamin D is, unfortunately, an imprecise term referring to one or more members of a group of steroid molecules. Vitamin D₃, also known as cholecalciferol is generated in the skin of animals when light energy is absorbed by a precursor molecule 7-dehydrocholesterol. Vitamin D is thus not a true vitamin, because individuals with adequate exposure to sunlight do not require dietary supplementation. There are also dietary sources of vitamin D, including egg yolk, fish oil and a number of plants. The plant form of vitamin D is called vitamin D₂ or ergosterol. However, natural diets typically do not contain adequate quantities of vitamin D, and exposure to sunlight or consumption of foodstuffs purposefully

supplemented with vitamin D are necessary to prevent deficiencies (*How et al., 1994*).

Vitamin D, as either D₃ or D₂, does not have significant biological activity. Rather, it must be metabolized within the body to the hormonally-active form known as 1, 25-dihydroxycholecalciferol. This transformation occurs in two steps, as depicted in Figure (1).

Within the liver, cholecalciferol is hydroxylated to 25-hydroxycholecalciferol by the enzyme 25-hydroxylase. Within the kidney, 25-hydroxycholecalciferol serves as a substrate for 1- α -hydroxylase, yielding 1,25-dihydroxycholecalciferol, the biologically active form. Each of the forms of vitamin D is hydrophobic, and is transported in blood bound to carrier proteins. The major carrier is called, appropriately, vitamin D-binding protein. The half-life of 25-hydroxycholecalciferol is several weeks, while that of 1, 25-dihydroxycholecalciferol is only a few hours (*How et al., 1994*).




Fig. (1): Metabolism of vitamin D (*How et al., 1994*).

Control of Vitamin D Synthesis:

Hepatic synthesis of 25-hydroxycholecalciferol is only loosely regulated, and blood levels of this molecule largely reflect the amount of vitamin D produced in the skin or ingested. In contrast, the activity of 1- α -hydroxylase in the kidney is tightly regulated and serves as the major control point in production of the active hormone. Interesting species differences exist in the ability to synthesize vitamin D through the sunlight-mediated pathway. The skin of humans, horses, pigs, rats, cattle and sheep contain adequate quantities of 7-dehydrocholesterol which can effectively be converted to cholecalciferol. In contrast, the skin of dogs and cats contains